Department of Clinical Hematology, Second Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, 710004, China.
Department of Pathology, Affiliated Hospital, Wuxi Medical School, Jiangnan University, Wuxi, 214062, Jiangsu, China.
Clin Exp Med. 2017 Nov;17(4):431-439. doi: 10.1007/s10238-017-0450-9. Epub 2017 Jan 24.
Multiple myeloma (MM) is a complex disease and is presently an incurable malignant plasma cell tumor. Although the introduction of proteasome inhibitor and the immunomodulators markedly improved the effect of myeloma therapy, most patients still suffer from relapse even with an initially effective therapy. Accumulating evidence suggests that immunotherapy is a promising option in treating MM. And T cell plays crucial role through inducing sustained immune response in vivo in the immunotherapy of tumors. In this article, we will discuss progress of several T cell-based immunotherapies with insight into how they eradicate myeloma cells and their disadvantages.
多发性骨髓瘤（MM）是一种复杂的疾病，目前是一种无法治愈的恶性浆细胞瘤。尽管蛋白酶体抑制剂和免疫调节剂的引入显著改善了骨髓瘤治疗的效果，但即使在最初有效的治疗后，大多数患者仍会复发。越来越多的证据表明，免疫疗法是治疗 MM 的一种有前途的选择。在肿瘤的免疫治疗中，T 细胞通过在体内诱导持续的免疫反应发挥关键作用。在本文中，我们将讨论几种基于 T 细胞的免疫疗法的进展，深入了解它们如何消除骨髓瘤细胞及其缺点。
